prof. dr. M.J. (Maarten) Postma

Professor Dept of Pharmacy & 2ndary appointment Professor UMCG

prof. dr. M.J. (Maarten) Postma
Telephone:
E-mail:
m.j.postma rug.nl

Research

  1. 2017
  2. Fugel, H-J., Nuijten, M., Postma, M., & Redekop, K. (2017). Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges. In M. Jakovljevic, & T. Yamada (Eds.), Role of health economic data in policy making and reimbursement of new medical technologies (pp. 14-20). Frontiers Media SA. https://doi.org/10.3389/978-2-88945-320-7
  3. 2015
  4. Smit, R., & Postma, M. (2015). Expressing the burden of tick-borne encephalitis (TBE) in disability-adjusted life years (DALYs) in Slovenia. In Gesundheit in den Regionen: Zwischen Versorgungsanspruch und Kostenverteilung (Vol. Proceedings:7, pp. 176)
  5. Postma, M., Carroll, S., & Branda, A. (2015). The societal role of lifelong vaccination. In M. Toumi (Ed.), The Economic Value of Vaccination: Why Prevention is Wealth. (Vol. 3, pp. 269962). Journal of Market Access & Health Policy .
  6. 2014
  7. Postma, M., & Boersma, C. (2014). Farmaco-economie. In HJ. Out, P. van Meurs, & R. van Olden (Eds.), Handboek farmaceutische geneeskunde (Vol. Hoofdstuk 7, pp. 99-118). Houten: Bohn, Stafleu, Van Loghum.
  8. Postma, M. (2014). Kosten van de zorg wegen we af tegen langer en/of aangenamer leven. In V. M. (Ed.), Gezonder ouder worden in Nederland (pp. 31-33). [Hoofdstuk 10] Breda: NPN Drukkers.
  9. 2013
  10. Vegter, S., van Boven, J., Hiddink, E. G., & Postma, M. (2013). Economische uitkomsten. In JJ. de Gier, ML. Bouvy, ACG. Egberts, & PAGM. de Smet (Eds.), Handboek farmaceutische patiëntenzorg: achtergronden en praktijk (Vol. Hoofdstuk 21, pp. 275-282)
  11. van Hulst, M., & Postma, M. (2013). Health economics of technologies in blood transfusion within the context of general HTAs. In C. T. Smit Sibinga (Ed.), Quality management in transfusion medicine (pp. 385-411). [Chapter XII] New York: Nova Science Publishers.
  12. Postma, M., Boersma, C., Vegter, S., VanDijck, D., & Annemans, L. (2013). Pharmacoeconomics of pharmacogenetics within the context of general health technology assessments. In Y-W. F. Lam, & LH. Cavallari (Eds.), Pharmacoeconomics (Vol. Chapter 12, pp. 429-450)
  13. 2012
  14. Krabbe, P., Postma, M., & Buskens, E. (2012). Keuzen in de zorg. In DJ. Bakker, D. Post, J. Polder, & M. Verkerk (Eds.), Een vitale toekomst : onze gezondheidszorg in 2040 (pp. 181-191). [Hoofdstuk 19] Amsterdam: Reed Business Media.
  15. Postma, M., & Hubben, G. (2012). The role of pharmaco-ecoinformatics in enhancing the pharmaco-economics context of decision making. In TM. Gasmelseid (Ed.), Pharmacoinformatics and drug discovery technologies: Theories and applications (pp. 44-52). [Chapter 4] Hershey: IGI Global.
  16. 2011
  17. Postma, M., de Wit, A., & Severens, H. (2011). Economische evaluatiestudies van publieke gezondheidszorg. In Economie van de volksgezondheid : Zorg Voor Gezondheid = Zorg Voor Welvaart Assen: Koninklijke Van Gorcum.
  18. 2010
  19. Welte, R., Leidl, R. M., Greiner, W., & Postma, M. (2010). Health economics of infectious diseases. In A. Krämer, M. Kretzschmar, & K. Krickeberg (Eds.), Modern infectious disease epidemiolgy (pp. 249-275). New York: Springer.
  20. 2009
  21. Toenders, WGM., & Postma, M. (2009). De vergoeding van geneesmiddelen: Goedkoop als het kan, duur als het moet. In H. Buurma, HJ. Beudeker, LTW. de Jong-van den Berg, & HG. Leufkens (Eds.), Het geneesmiddel (5e druk ed., pp. 83-99). [Hoofdstuk 5] Maarssen: Elsevier.
  22. Bos, J. M., & Postma, M. (2009). Economics and vaccines. In VR. Preedy, & RR. Watson (Eds.), Handbook of disease burdens and quality of life measures (pp. 1336-1350). New York: Springer.
  23. Postma, M., & van Hulst, M. (2009). Net monetary benefit. In M. W. Kattan (Ed.), Encyclopedia of medical decision making Ohio: SAGE Publications Inc..
  24. Postma, M. (2009). Sensitivity analysis. In R. JG. Arnold (Ed.), Pharmacoeconomics: from theory to practice (Vol. Chapter 12, pp. 163-174). Boca Raton: Taylor & Francis Group.
  25. 2005
  26. van Luijn, J. C. F., & Postma, M. (2005). Regulering van de vraag naar geneesmiddelen. In H. Buurma, H. J. Beudeker, L. T. W. de Jong-van den Berg, & H. G. M. Leufkens (Eds.), Het geneesmiddel (pp. 86 - 105). Maarssen: Elsevier.
  27. 2004
  28. Postma, M., Wiessing, L. G., & Jager, J. C. (2004). Updated healthcare cost estimate for drug-related hepatitis C infections in the European Union. In J. Jager, W. Limburg, M. Kretzschmar, M. Postma, & L. Wiessing (Eds.), EMCDDA Monographs. Hepatitis C and injecting drug use: impact, costs and policy options (pp. 203 - 16). Luxembourg: Office for official publications of the european communities.
  29. 2002
  30. van Hulst, M., & Postma, MJ. (2002). Cost-effectiveness of alternatives to allogeneic blood transfusion; Reviewing the available evidence. In CTS. Sibinga, & RY. Dodd (Eds.), TRANSMISSIBLE DISEASES AND BLOOD TRANSFUSION, PROCEEDINGS (pp. 131-142). (DEVELOPMENTS IN HEMATOLOGY AND IMMUNOLOGY; Vol. 37). DORDRECHT: Springer.
  31. 2001
  32. Postma, MJ., Los, APM., Ruitenberg, EJ., & Sibinga, CTS. (2001). Cost-effectiveness of HIVNAT screening for Dutch donors. In CTS. Sibinga, & JD. Cash (Eds.), TRANSFUSION MEDICINE: QUO VADIS? WHAT HAS BEEN ACHIEVED, WHAT IS TO BE EXPECTED (pp. 45-51). (DEVELOPMENTS IN HEMATOLOGY AND IMMUNOLOGY; Vol. 36). DORDRECHT: Springer.
  33. Postma, M., Heijnen, M-LA., & Jager, JC. (2001). Kosten-effectiviteitsanalyse van pneumokokkenvaccinatie voor Nederlandse 65+'ers. In R. van Furth (Ed.), Pneumokokkeninfecties in de 21e eeuw (pp. 71-80). (Boerhaave Cursussen).
  34. Postma, M., Tolley, K., & Jager, JC. (2001). Modelling the health-care costs of drug-use-related disease: Part V: Economic Models, Chapter 12. In Modelling drug use: methods to quantify and understand hidden processes (pp. 205-220). (EMCDDA Scientific Monograph Series).
  35. Jager, JC., Postma, M., & Achterberg , PW. (2001). Part IV: Modelling the health consequences of drug use, Chapter 11: Developing multinational scenario analysis of health impacts of drug use. In Modelling drug use: methods to quantify and understand hidden processes (pp. 183-201). (EMCDDA Scientific Monograph Series ).
  36. Godfrey, C., Parrot, S., Sutton, M., Waby, V., Young, P., Comiskey , C., ... Wiessing, L. (2001). Part 1: What is modelling and how can it be used? In Modelling drug use: methods to quantify and understand hidden processes (Vol. chapter 2, pp. 33-52). (EMCDDA Scientific Monograph Series ).
  37. Postma, M., Smit Sibinga, C. T., & Ruitenberg, EJ. (2001). Pharmaco-economics of transfusion safety. In CT. Smit Sibinga, & JD. Cash (Eds.), Quo Vadis (pp. 45-51). Londen: Kluwer.

ID: 193217